TMEM16A Potentiators: Is There a Need for New Modulators in Cystic Fibrosis?
- PMID: 31913655
- PMCID: PMC7159432
- DOI: 10.1164/rccm.201912-2519ED
TMEM16A Potentiators: Is There a Need for New Modulators in Cystic Fibrosis?
Comment on
-
TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.Am J Respir Crit Care Med. 2020 Apr 15;201(8):946-954. doi: 10.1164/rccm.201908-1641OC. Am J Respir Crit Care Med. 2020. PMID: 31898911 Free PMC article.
References
-
- Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394:1940–1948. - PMC - PubMed
-
- Scott DW, Walker MP, Sesma J, Wu B, Stuhlmiller TJ, Sabater JR, et al. SPX-101 is a novel epithelial sodium channel-targeted therapeutic for cystic fibrosis that restores mucus transport. Am J Respir Crit Care Med. 2017;196:734–744. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
